|
|
|
Sunday, March 2, 2008 — 7:30 PM, Convention Center 102/104/106
|
- HPV Testing and Beyond: When and How to Validate and Implement New Assays in the Era of Molecular Cytopathology
|
|
Moderator:
|
Douglas P. Clark, The Johns Hopkins Medical Institutions, Baltimore, MD
|
|
|
Disclosure:
|
In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. Dr. Mark H. Stoler indicated he is a consultant for Merck, Qiagen, Ventana and Roche Molecular. Dr. Douglas P. Clark indicated he is a consultant and receives grant/research support from TriPath Oncology (BD). All other faculty members for this Symposium have indicated they have no disclosures to make.
|
Click the button above to add this event to your Itinerary Planner...
 Click here to view (or print) handout in single page format for the entire meeting.
Note: Any slides will be printed in color.
Click any blue title below to display and print the handout for individual lecture(s):
| 7:30 | Molecular Cytopathology: Promises and Challenges - Douglas P. Clark, The Johns Hopkins Medical Institutions, Baltimore, MD |
| 7:45 | HPV Testing and Understanding Validity: A Tough Row to Hoe - Mark H. Stoler, University of Virginia Health Science, Charlottesville, VA |
| 8:30 | Entering the Molecular Age of Cervical Cancer Prevention: What's New and How Do We Bring Order to the Chaos? - Philip E. Castle, National Cancer Institute, NIH, DHHS, Bethesda, MD |
| 9:15 | Molecular Cytopathology: Future Directions (no handout available) - Douglas P. Clark, The Johns Hopkins Medical Institutions, Baltimore, MD |
|
|
|
